Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in: Diabetes Therapy 5/2024

Open Access 18-03-2024 | Insulins | Review

Insulin Use During Gestational and Pre-existing Diabetes in Pregnancy: A Systematic Review of Study Design

Authors: Kristin Castorino, Beatrice Osumili, Theophilus Lakiang, Kushal Kumar Banerjee, Andrea Goldyn, Carolina Piras de Oliveira

Published in: Diabetes Therapy | Issue 5/2024

Login to get access

Abstract

Introduction

Insulin is the first-line pharmacologic therapy for women with diabetes in pregnancy. However, conducting well-designed randomized clinical trials (RCTs) and achieving recommended glycemic targets remains a challenge for this unique population. This systematic literature review (SLR) aimed to understand the evidence for insulin use in pregnancy and the outcome metrics most often used to characterize its effect on glycemic, maternal and fetal outcomes in gestational diabetes mellitus (GDM) and in pregnant women with diabetes.

Methods

An SLR was conducted using electronic databases in Medline, EMBASE via Ovid platform, evidence-based medicine reviews (2010–2020) and conference proceedings (2018–2019). Studies were included if they assessed the effect of insulin treatment on glycemic, maternal or fetal outcomes in women with diabetes in pregnancy. Studies on any type of diabetes other than gestational or pre-existing diabetes as well as non-human studies were excluded.

Results

In women diagnosed with GDM or pre-existing diabetes, most studies compared treatment of insulin with metformin (n = 35) followed by diet along with lifestyle intervention (n = 24) and glibenclamide (n = 12). Most studies reporting on glycemic outcomes compared insulin with metformin (n = 22) and glibenclamide (n = 4). Fasting blood glucose was the most reported clinical outcome of interest. Among the studies reporting maternal outcomes, method of delivery and delivery complications were most commonly reported. Large for gestational age, stillbirth and perinatal mortality were the most common fetal outcomes reported.

Conclusion

This SLR included a total of 108 clinical trials and observational studies with diverse populations and treatment arms. Outcomes varied across the studies, and a lack of consistent outcome measures to manage diabetes in pregnant women was observed. This elucidates a need for global consensus on study design and standardized clinical, maternal and fetal outcomes metrics.
Appendix
Available only for authorised users
Literature
1.
Metzger BE. Proceedings of the fourth international workshop conference on gestational diabetes mellitus. Diabetes Care. 1998;21(2):B1–167.
2.
3.
4.
Association AD. Gestational diabetes mellitus. Diabetes Care. 2004;27(suppl 1):s88–90.CrossRef
5.
Tyrala EE. The infant of the diabetic mother. Obstet Gynecol Clin. 1996;23(1):221–41.CrossRef
6.
Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 2011;45(1):9–16.PubMedCrossRef
7.
Serlin DC, Lash RW. Diagnosis and management of gestational diabetes mellitus. (0002-838X (Print)).
8.
Pantea-Stoian A, Stoica RA, Stefan SD. Insulin therapy in gestational diabetes. Gestational diabetes mellitus—an overview with some recent advances. London: IntechOpen; 2019.
9.
Bulletins-Obstetrics C. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49–64.CrossRef
10.
Cho N, Shaw J, Karuranga S, Huang YD, da Rocha Fernandes J, Ohlrogge A, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.PubMedCrossRef
11.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 15. Management of diabetes in pregnancy: standards of care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S254–66.PubMedCrossRef
12.
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119.PubMedCrossRef
13.
14.
Oude Rengerink K, Logtenberg S, Hooft L, Bossuyt PM, Mol BW. Pregnant womens’ concerns when invited to a randomized trial: a qualitative case control study. BMC Pregnancy Childbirth. 2015;15(1):1–11.CrossRef
15.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.PubMedCrossRef
16.
Dissemination C. Systematic reviews: CRD’s guidance for undertaking reviews in healthcare. York: University of York NHS Centre for Reviews & Dissemination; 2009.
17.
18.
19.
20.
Galal M, El Bassiou WM, Sherif L. Metformin versus insulin in treatment of gestational diabetes mellitus: a randomized controlled trial. Res J Obstet Gynecol. 2019;12(1):23–7.CrossRef
21.
Wasim T, Shaukat S, Javaid L, Mukhtar S, Amer WJ. Comparison of metformin and insulin for management of gestational diabetes mellitus: a randomized control trial. Pak J Med Sci. 2019;13:823–7.
22.
Ashoush S, El-Said M, Fathi H, Abdelnaby M. Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus. J Obstet Gynaecol Res. 2016;42(6):640–7.PubMedCrossRef
23.
Zawiejska A, Wender-Ozegowska E, Grewling-Szmit K, Brazert M, Brazert. Short-term antidiabetic treatment with insulin or metformin has a similar impact on the components of metabolic syndrome in women with gestational diabetes mellitus requiring antidiabetic agents: Results of a prospective, randomised study. J Physiol Pharmacol. 2016;67(2):227–33.PubMed
24.
Khan R, Mukhtar A, Khawar A. Comparison of metformin with insulin in the management of gestational diabetes. Med Forum Mon. 2017;28(11):105–9.
25.
Arshad R, Karim N, Ara HJ. Effects of insulin on placental, fetal and maternal outcomes in gestational diabetes mellitus. Pak J Med Sci. 2014;30(2):240–4.PubMedPubMedCentral
26.
Subhash Somani P, Kumar Sahana P, Chaudhuri P, Sengupta N. Treatment of gestational diabetes mellitus: insulin or metformin? J Evol Med Dent Sci. 2016;5(63):4423–9.CrossRef
27.
Ji J, He Z, Yang Z, Mi Y, Guo N, Zhao H, et al. Comparing the efficacy and safety of insulin detemir versus neutral protamine Hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. BMJ Open Diabetes Res Care. 2020;8(1).
28.
Simeonova-Krstevska S, Bogoev M, Bogoeva K, Zisovska E, Samardziski I, Velkoska-Nakova V, et al. Maternal and neonatal outcomes in pregnant women with gestational diabetes mellitus treated with diet, metformin or insulin. Open Access Maced J Med Sci. 2018;6(5):803–7.PubMedPubMedCentralCrossRef
29.
Ozgu-Erdinc AS, Iskender C, Uygur D, Oksuzoglu A, Seckin KD, Yeral MI, et al. One-hour versus two-hour postprandial blood glucose measurement in women with gestational diabetes mellitus: which is more predictive? Endocrine. 2016;52(3):561–70.PubMedCrossRef
30.
Yanagisawa K, Muraoka M, Takagi K, Ichimura Y, Kambara M, Sato A, et al. Assessment of predictors of insulin therapy in patients with gestational diabetes diagnosed according to the IADPSG criteria. Diabetol Int. 2016;7(4):440–6.PubMedPubMedCentralCrossRef
31.
Tang L, Xu S, Li P, Li L. Predictors of insulin treatment during pregnancy and abnormal postpartum glucose metabolism in patients with gestational diabetes mellitus. Diabetes Metab Syndr Obes. 2019;12:2655–65.PubMedPubMedCentralCrossRef
32.
Benhalima K, Robyns K, Van Crombrugge P, Deprez N, Seynhave B, Devlieger R, et al. Differences in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes. BMC Pregnancy Childbirth. 2015;15:271.PubMedPubMedCentralCrossRef
33.
Ghomian N, Vahed SHM, Firouz S, Yaghoubi MA, Mohebbi M, Sahebkar A. The efficacy of metformin compared with insulin in regulating blood glucose levels during gestational diabetes mellitus: a randomized clinical trial. J Cell Physiol. 2019;234(4):4695–701.PubMedCrossRef
34.
Eid SR, Moustafa RSI, Salah MM, Hanafy SK, Aly RH, Mostafa WFG, et al. Is metformin a viable alternative to insulin in the treatment of gestational diabetes mellitus (GDM)? Comparison of maternal and neonatal outcomes. Egypt Pediatr Assoc Gazette. 2018;66(1):15–21.CrossRef
35.
Hamadani A, Zahid S, Butt ZB. Metformin versus insulin treatment in gestational diabetes in pregnancy and their effects on neonatal birthweight. Pak J Med Sci. 2017;11:914–6.
36.
Ainuddin J, Karim N, Hasan AA, Naqvi SA. Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. Diabetes Res Clin Pract. 2015;107(2):290–9.PubMedCrossRef
37.
Ruholamin S, Eshaghian S, Allame Z. Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: a randomized clinical trial. J Res Med Sci. 2014;19(10):970.PubMedPubMedCentral
38.
Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab. 2013;15(3):246–51.PubMedCrossRef
39.
Niromanesh S, Alavi A, Sharbaf FR, Amjadi N, Moosavi S, Akbari S. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. Diabetes Res Clin Pract. 2012;98(3):422–9.PubMedCrossRef
40.
Hassan JA, Karim N, Sheikh Z. Metformin prevents macrosomia and neonatal morbidity in gestational diabetes. J Pak J Med Sci. 2012;28(3):384–9.
41.
Ijas H, Vaarasmaki M, Morin-Papunen L, Keravuo R, Ebeling T, Saarela T, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG. 2011;118(7):880–5.PubMedCrossRef
42.
Mirzamoradi M, Heidar Z, Faalpoor Z, Naeiji Z, Jamali R. Comparison of glyburide and insulin in women with gestational diabetes mellitus and associated perinatal outcome: a randomized clinical trial. Acta Med Iran. 2015;53:97–103.PubMed
43.
Huhtala MS, Tertti K, Pellonpera O, Ronnemaa T. Amino acid profile in women with gestational diabetes mellitus treated with metformin or insulin. Diabetes Res Clin Pract. 2018;146:8–17.PubMedCrossRef
44.
Ainuddin JA, Karim N, Zaheer S, Ali SS, Hasan AA. Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. J Diabetes Res. 2015;2015: 325851.PubMedPubMedCentralCrossRef
45.
Varghese R, Thomas B, Hail MA, Rauf A, Sadi MA, Sualiti AA, et al. The prevalence, risk factors, maternal and fetal outcomes in gestational diabetes mellitus. J Int J Drug Dev Res. 2012;4(3):356–68.
46.
Bogdanet D, Egan A, Reddin C, Kirwan B, Carmody L, Dunne F. ATLANTIC DIP: despite insulin therapy in women with IADPSG diagnosed GDM, desired pregnancy outcomes are still not achieved. What are we missing? Diabetes Res Clin Pract. 2018;136:116–23.PubMedCrossRef
47.
Donovan LE, Boyle SL, McNeil DA, Pedersen SD, Dean SR, Wood S, et al. Label of gestational diabetes mellitus affects caesarean section and neonatal intensive care unit admission without conventional indications. Can J Diabetes. 2012;36(2):58–63.CrossRef
48.
Fishel Bartal M, Ward C, Refuerzo JS, Ashimi SS, Joycelyn CA, Chen HY, et al. Basal insulin analogs versus neutral protamine Hagedorn for type 2 diabetics. Am J Perinatol. 2020;37(1):30–6.PubMedCrossRef
49.
Landi SN, Radke S, Boggess K, Engel SM, Sturmer T, Howe AS, et al. Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. Pharmacoepidemiol Drug Saf. 2019;28(12):1609–19.PubMedCrossRef
50.
Morais Rodrigues I, Figueiredo A, Pereira N, Amaral N, Pratas S, Valadas C, et al. Metformin as a safe option to insulin in gestational diabetes mellitus: a retrospective study. SN Compr Clin Med. 2020;2(3):272–7.CrossRef
51.
Negrato CA, Rafacho A, Negrato G, Teixeira MF, Araujo CA, Vieira L, et al. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89(1):46–51.PubMedCrossRef
52.
Hickman MA, McBride R, Boggess KA, Strauss R. Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol. 2013;30(6):483–90.PubMedCrossRef
53.
Garcia-Dominguez M, Herranz L, Hillman N, Martin-Vaquero P, Janez M, Moya-Chimenti E, et al. Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus. Med Clin (Barc). 2011;137(13):581–6.PubMedCrossRef
54.
Senat MV, Affres H, Letourneau A, Coustols-Valat M, Cazaubiel M, Legardeur H, et al. Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes: a randomized clinical trial. JAMA. 2018;319(17):1773–80.PubMedPubMedCentralCrossRef
55.
Koren R, Ashwal E, Hod M, Toledano Y. Insulin detemir versus glyburide in women with gestational diabetes mellitus. Gynecol Endocrinol. 2016;32(11):916–9.PubMedCrossRef
56.
Mesdaghinia E, Samimi M, Homaei Z, Saberi F, Moosavi SGA, Yaribakht M. Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial. Int J Prev Med. 2013;4(3):327.PubMedPubMedCentral
57.
Hod M, Mathiesen ER, Jovanovic L, McCance DR, Ivanisevic M, Duran-Garcia S, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27(1):7–13.PubMedCrossRef
58.
Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral hypoglycemic glibenclamide: can it be a substitute to insulin in the management of gestational diabetes mellitus? A comparative study. J South Asian Fed Obstet Gynaecol. 2012;4(1):28–31.CrossRef
59.
Camelo Castillo W, Boggess K, Sturmer T, Brookhart MA, Benjamin DK Jr, Jonsson FM. Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes. JAMA Pediatr. 2015;169(5):452–8.PubMedCrossRef
60.
Hedderson MM, Xu F, Neugebauer R, Ferrara A. editors. Glyburide versus insulin for the treatment of women with gestational diabetes in Kaiser Permanente Northern California. In: Pharmacoepodemiology and drug safety. Hoboken: Wiley; 2018.
61.
Neff KJ, Forde R, Gavin C, Byrne MM, Firth RG, Daly S, et al. Pre-pregnancy care and pregnancy outcomes in type 1 diabetes mellitus: a comparison of continuous subcutaneous insulin infusion and multiple daily injection therapy. Ir J Med Sci. 2014;183(3):397–403.PubMedCrossRef
62.
Abell SK, Suen M, Pease A, Boyle JA, Soldatos G, Regan J, et al. Pregnancy outcomes and insulin requirements in women with type 1 diabetes treated with continuous subcutaneous insulin infusion and multiple daily injections: cohort study. Diabetes Technol Ther. 2017;19(5):280–7.PubMedCrossRef
63.
Billionnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60(4):636–44.PubMedPubMedCentralCrossRef
64.
Koivunen S, Kajantie E, Torkki A, Bloigu A, Gissler M, Pouta A, et al. The changing face of gestational diabetes: the effect of the shift from risk factor-based to comprehensive screening. Eur J Endocrinol. 2015;173(5):623–32.PubMedCrossRef
65.
Liang H-L, Ma S-J, Xiao Y-N, Tan H-Z. Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: an updated PRISMA-compliant network meta-analysis. Medicine. 2017;96(38):e7939.PubMedPubMedCentralCrossRef
66.
Das V, Priyanka Y, Smriti A, Anjoo A, Namrata K. Oral/free communication session abstracts. 2018;143(S3):158–542.
67.
Behrashi M, Samimi M, Ghasemi T, Saberi F, Atoof F. Comparison of glibenclamide and insulin on neonatal outcomes in pregnant women with gestational diabetes. Int J Prev Med. 2016;7:88–88.PubMedPubMedCentralCrossRef
68.
Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Francisco RP. Randomized trial of metformin vs insulin in the management of gestational diabetes. Am J Obstet Gynecol. 2013;209(1):34 (e31–37).CrossRef
69.
Balaji V, Balaji MS, Alexander C, et al. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecol Endocrinol. 2012;28(7):529–32.PubMedCrossRef
70.
Herrera KM, Rosenn BM, Foroutan J, et al. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes. Am J Obstet Gynecol. 2015;213(3):426 (e421–427).CrossRef
71.
Refuerzo JS, Gowen R, Pedroza C, Hutchinson M, Blackwell SC, Ramin S. A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. Am J Perinatol. 2015;30(2):163–70.PubMed
72.
Han D, Lu B, Pang Z. Efficacy of metformin combined with insulin lispro on gestational diabetes and effects on serum miR-16. Int J Clin Exp Med. 2020;13(3):1728–35.
73.
Krishnakumar S, Govindarajulu Y, Vishwanath U, Nagasubramanian VR, Palani T. Impact of patient education on KAP, medication adherence and therapeutic outcomes of metformin versus insulin therapy in patients with gestational diabetes: a hospital based pilot study in South India. Diabetes Metab Syndr. 2020;14(5):1379–83.PubMedCrossRef
74.
Osuagwu UL, Fuka F, Agho K, Khan A, Simmons D. Adverse maternal outcomes of Fijian women with gestational diabetes mellitus and the associated risk factors. Reprod Sci. 2020;27(11):2029–37.PubMedCrossRef
75.
Zaharieva D, Krishnamurthy B, Teng J, et al. Assessment of glycaemia by fingerstick blood glucose monitoring may underestimate the requirement for insulin to address elevated nocturnal glucose levels in women with GDM. Paper presented at: Diabetes Technology and Therapeutics, 2020.
76.
Cade TJ, Polyakov A, Brennecke SP. Implications of the introduction of new criteria for the diagnosis of gestational diabetes: a health outcome and cost of care analysis. BMJ Open. 2019;9(1): e023293.PubMedPubMedCentralCrossRef
77.
Meghelli L, Vambergue A, Drumez E, Deruelle P. Complications of pregnancy in morbidly obese patients: what is the impact of gestational diabetes mellitus? J Gynecol Obstet Hum Reprod. 2020;49(1): 101628.PubMedCrossRef
78.
Munn AJ, Hersh AR, Vinson AR, Brennan TD, Valent AM, Caughey AB. 492: Neonatal outcomes in gestational diabetes managed with insulin vs. glyburide therapy: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019;220(1):S330.CrossRef
79.
Ng A, Liu A, Nanan R. Association between insulin and post-caesarean resuscitation rates in infants of women with GDM: a retrospective study. J Diabetes. 2019;12(2):151–7.PubMedCrossRef
80.
Christian SJ, Boama V, Satti H, et al. Metformin or insulin: logical treatment in women with gestational diabetes in the Middle East, our experience. BMC Res Notes. 2018;11(1):426.PubMedPubMedCentralCrossRef
81.
Leung A, Yu G, Smith L. 993: Adverse pregnancy outcomes with glyburide vs insulin among patients with gestational diabetes established by the International Association of Diabetes and Pregnancy Study Group (IADPSG). Am J Obstet Gynecol. 2018;218(1):S586.CrossRef
82.
McGrath RT, Glastras SJ, Scott ES, Hocking SL, Fulcher GR. Outcomes for women with gestational diabetes treated with metformin: a retrospective, case–control study. J Clin Med. 2018;7(3):50.PubMedPubMedCentralCrossRef
83.
Meregaglia M, Dainelli L, Banks H, Benedetto C, Detzel P, Fattore G. The short-term economic burden of gestational diabetes mellitus in Italy. BMC Pregnancy Childbirth. 2018;18(1):58.PubMedPubMedCentralCrossRef
84.
Patanjali CP, Ayyar V, Bantwal G, George B, Perumal N. Maternal and neonatal outcomes in gestational diabetes treated with metformin. Indian J Endocrinol Metab. 2018;22:S44 (ESICON 2018).
85.
Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res Care. 2018;6(1): e000456.PubMedPubMedCentralCrossRef
86.
Vanlalhruaii, Dasgupta R, Ramachandran R, et al. How safe is metformin when initiated in early pregnancy? A retrospective 5-year study of pregnant women with gestational diabetes mellitus from India. Diabetes Res Clin Pract. 2018;137:47–55.PubMedCrossRef
87.
Bowker SL, Savu A, Yeung RO, Johnson JA, Ryan EA, Kaul P. Patterns of glucose-lowering therapies and neonatal outcomes in the treatment of gestational diabetes in Canada, 2009–2014. Diabet Med. 2017;34(9):1296–302.PubMedCrossRef
88.
Gibbons A, Flatley C, Kumar S. Cerebroplacental ratio in pregnancies complicated by gestational diabetes mellitus. Ultrasound Obstet Gynecol. 2017;50(2):200–6.PubMedCrossRef
89.
Olmos PR, Borzone GR. Basal-bolus insulin therapy reduces maternal triglycerides in gestational diabetes without modifying cholesteryl ester transfer protein activity. J Obstet Gynaecol Res. 2017;43(9):1397–404.PubMedCrossRef
90.
Xie J, Dai L, Tang X. The comparison of the safety and effectiveness of multiple insulin injections and insulin pump therapy in treating gestational diabetes. Biomed Res. 2017;28(18):7830–3.
91.
Fazel-Sarjoui Z, Namin AK, Kamali M, Namin NK, Tajik A. Complications in neonates of mothers with gestational diabetes mellitus receiving insulin therapy versus dietary regime. Int J Reprod BioMed. 2016;14(4):275.PubMedPubMedCentral
92.
Ito Y, Shibuya M, Hosokawa S, et al. Indicators of the need for insulin treatment and the effect of treatment for gestational diabetes on pregnancy outcomes in Japan. Endocr J. 2016;63(3):231–7.PubMedCrossRef
93.
Koning SH, Hoogenberg K, Scheuneman KA, et al. Neonatal and obstetric outcomes in diet- and insulin-treated women with gestational diabetes mellitus: a retrospective study. BMC Endocr Disord. 2016;16(1):52.PubMedPubMedCentralCrossRef
94.
Saleem N, Godman B, Hussain S. Comparing twice-versus four-times daily insulin in mothers with gestational diabetes in Pakistan and its implications. J Comp Effect Res. 2016;5(5):453–9.CrossRef
95.
Watanabe M, Katayama A, Kagawa H, Ogawa D, Wada J. Risk factors for the requirement of antenatal insulin treatment in gestational diabetes mellitus. J Diabetes Res. 2016;2016:9648798.PubMedPubMedCentralCrossRef
96.
Cosson E, Bihan H, Reach G, Vittaz L, Carbillon L, Valensi P. Psychosocial deprivation in women with gestational diabetes mellitus is associated with poor fetomaternal prognoses: an observational study. BMJ Open. 2015;5(3): e007120.PubMedPubMedCentralCrossRef
97.
Inocêncio G, Braga A, Lima T, et al. Which factors influence the type of delivery and cesarean section rate in women with gestational diabetes? J Reprod Med. 2015;60(11–12):529–34.PubMed
98.
Kopec JA, Ogonowski J, Rahman MM, Miazgowski T. Patient-reported outcomes in women with gestational diabetes: a longitudinal study. Int J Behav Med. 2015;22(2):206–13.PubMedCrossRef
99.
You JY, Choi SJ, Roh CR, Kim JH, Oh SY. Pregnancy and neonatal outcomes in gestational diabetes treated with regular insulin or fast-acting insulin analogues. Gynecol Obstet Invest. 2016;81(3):232–7.PubMedCrossRef
100.
Deepaklal M, Joseph K, Kurian R, Thakkar NA. Efficacy of insulin lispro in improving glycemic control in gestational diabetes. Indian J Endocrinol Metab. 2014;18(4):491.PubMedPubMedCentralCrossRef
101.
Konig AB, Junginger S, Reusch J, Louwen F, Badenhoop K. Gestational diabetes outcome in a single center study: higher BMI in children after six months. Horm Metab Res. 2014;46(11):804–9.PubMedCrossRef
102.
Marques P, Carvalho MR, Pinto L, Guerra S. Metformin safety in the management of gestational diabetes. Endocr Pract. 2014;20(10):1022–31.PubMedCrossRef
103.
Al-Rubeaan KA, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, Ibrahim HM. A web-based interactive diabetes registry for health care management and planning in Saudi Arabia. J Med Internet Res. 2013;15(9):e202
104.
Hernandez-Rivas E, Flores-Le Roux JA, Benaiges D, et al. Gestational diabetes in a multiethnic population of Spain: clinical characteristics and perinatal outcomes. Diabetes Res Clin Pract. 2013;100(2):215–21.PubMedCrossRef
105.
Latif L, Hyer S, Shehata H. Metformin effects on treatment satisfaction and quality of life in gestational diabetes. Br J Diabetes Vasc Dis. 2013;13(4):178–82.CrossRef
106.
Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. J Obstet Gynaecol Res. 2013;39(6):1147–52.PubMedCrossRef
107.
Cheng YW, Chung JH, Block-Kurbisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2012;25(4):379–84.PubMedCrossRef
108.
Thomas N, Chinta AJ, Sridhar S, Kumar M, Kuruvilla KA, Jana AK. Perinatal outcome of infants born to diabetic mothers in a developing country-comparison of insulin and oral hypoglycemic agents. Indian Pediatr. 2013;50(3):289–93.PubMedCrossRef
109.
Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011;28(9):1082–7.PubMedCrossRef
110.
Wong VW, Jalaludin B. Gestational diabetes mellitus: who requires insulin therapy? Aust NZ J Obstet Gynaecol. 2011;51(5):432–6.CrossRef
111.
Flores-Le Roux JA, Chillaron JJ, Goday A, et al. Peripartum metabolic control in gestational diabetes. Am J Obstet Gynecol. 2010;202(6):568 (e561–566).CrossRef
112.
Demasio KA, Richley M. 434: Neonatal hypoglycemia; does basal insulin choice matter? Am J Obstet Gynecol. 2020;222(1):S285.CrossRef
113.
Kong L, Nilsson IAK, Gissler M, Lavebratt C. Associations of Maternal Diabetes and Body Mass Index With Offspring Birth Weight and Prematurity. JAMA Pediatr. 2019;173(4):371–78.
114.
Mathiesen E, Alibegovic A, Husemoen L, et al. Risk of major congenital malformations, perinatal or neonatal death with insulin detemir vs other basal insulins in pregnant women with pre-existing diabetes: EVOLVE study. Paper presented at: Diabetologia 2020.
115.
Sperling M, Bentley J, Girsen A, et al. 759: Comparing insulin, metformin, and glyburide in treating diabetes in pregnancy and analyzing obstetric outcomes. Am J Obstet Gynecol. 2020;222(1):S481.CrossRef
116.
Alexander LD, Tomlinson G, Feig DS. Predictors of large-for-gestational-age birthweight among pregnant women with type 1 and type 2 diabetes: a retrospective cohort study. Can J Diabetes. 2019;43(8):560–6.PubMedCrossRef
117.
Christman L, Piszczek J, Magee M, Ferris L, Duong J, Farley D. Patients with diabetes mellitus managed with insulin detemir: hospital outcomes [18E]. Obstet Gynecol. 2019;133:56S.CrossRef
118.
Sleeman A, Odom J, Schellinger M. Comparison of hypoglycemia and safety outcomes with long-acting insulins versus insulin NPH in pregestational and gestational diabetes. Ann Pharmacother. 2020;54(7):669–75.PubMedCrossRef
119.
Smrz S, Finneran MM, Landon MB, Gabbe SG. Difference in glycemic profile with the pump vs multiple daily injections in treating type 1 diabetes in pregnancy [32F]. Obstet Gynecol. 2019;133:70S-71S.CrossRef
120.
Vasquez BA, Sarumi M, Shultz L, Bedell J, Gherman R, Johnson MJ. Glycemic efficacy with U-500 insulin in pregnancy: a retrospective cross-over study [21K]. Obstet Gynecol. 2019;133:123S.CrossRef
121.
Gupta S, Gupta K, Gathe S, Bamhra P, Gupta S. Insulin therapy in women with pregestational type 2 diabetes and its relevance to maternal and neonatal complications. Int J Diabetes Dev Ctries. 2018;38(1):47–54.CrossRef
122.
Sunjaya AF, Sunjaya AP. Comparing outcomes of nutrition therapy, insulin and oral anti-diabetics in managing diabetes mellitus in pregnancy: retrospective study and review of current guidelines. Diabetes Metab Syndr. 2019;13(1):104–9.PubMedCrossRef
123.
Stanirowski PJ, Szukiewicz D, Pyzlak M, Abdalla N, Sawicki W, Cendrowski K. Impact of pre-gestational and gestational diabetes mellitus on the expression of glucose transporters GLUT-1, GLUT-4 and GLUT-9 in human term placenta. Endocrine. 2017;55(3):799–808.PubMedCrossRef
124.
Dalfra MG, Soldato A, Moghetti P, et al. Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study. J Matern Fetal Neonatal Med. 2016;29(7):1061–5.PubMedCrossRef
125.
Becquet O, El Khabbaz F, Alberti C, et al. Insulin treatment of maternal diabetes mellitus and respiratory outcome in late-preterm and term singletons. BMJ Open. 2015;5(6): e008192.PubMedPubMedCentralCrossRef
126.
Colatrella A, Visalli N, Abbruzzese S, Leotta S, Bongiovanni M, Napoli A. Comparison of insulin lispro protamine suspension with NPH insulin in pregnant women with type 2 and gestational diabetes mellitus: maternal and perinatal outcomes. Int J Endocrinol. 2013;2013: 151975.PubMedPubMedCentralCrossRef
127.
Fresa R, Visalli N, Di Blasi V, et al. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study. Diabetes Technol Ther. 2013;15(4):328–34.PubMedCrossRef
128.
Bruttomesso D, Bonomo M, Costa S, et al. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab. 2011;37(5):426–31.PubMedCrossRef
Metadata
Title
Insulin Use During Gestational and Pre-existing Diabetes in Pregnancy: A Systematic Review of Study Design
Authors
Kristin Castorino
Beatrice Osumili
Theophilus Lakiang
Kushal Kumar Banerjee
Andrea Goldyn
Carolina Piras de Oliveira
Publication date
18-03-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01541-6

Other articles of this Issue 5/2024

Diabetes Therapy 5/2024 Go to the issue

Original Research

Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study

Study Protocol

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

Review

Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis

Original Research

Validity of Montreal Cognitive Assessment to Detect Cognitive Impairment in Individuals with Type 2 Diabetes

Original Research

Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity

Review

The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits